CLINICAL RESEARCH
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients
Kwang Kon Koh, MD, FACC*,*,
Jeong Yeal Ahn, MD ,
Seung Hwan Han, MD*,
Dae Sung Kim, MD ,
Dong Kyu Jin, MD*,
Hyung Sik Kim, MD ,
Mi-Seung Shin, MD*,
Tae Hoon Ahn, MD*,
In Suck Choi, MD* and
Eak Kyun Shin, MD*
* Departments of Cardiology, Gachon Medical School, Incheon, South Korea
Clinical Pathology, Gachon Medical School, Incheon, South Korea
Radiology, Gachon Medical School, Incheon, South Korea
Preventive Medicine (Biostatistics), Gachon Medical School, Incheon, South Korea
Manuscript received November 7, 2002;
accepted December 6, 2002.
* Reprint requests and correspondence: Dr. Kwang Kon Koh, Vascular Medicine and Atherosclerosis Unit, Cardiology, Gil Heart Center, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, Incheon, South Korea 405-760.
kwangk{at}ghil.com
OBJECTIVES: We investigated the vascular effects of candesartan in hypertensive patients.
BACKGROUND: The renin-angiotensin system may contribute to atherogenesis through the promotion of endothelial dysfunction. The plausible mechanisms are that angiotensin II promotes superoxide anion generation, endothelial dysfunction, inflammation, and impaired fibrinolysis. The effects of candesartan on these conditions have not been clearly observed.
METHODS: We administered placebo or candesartan 16 mg daily during two months to 45 patients with mild-to-moderate hypertension. This was a randomized, double-blind, placebo-controlled, crossover study in design.
RESULTS: Candesartan did not significantly change lipoprotein levels. However, compared with placebo, candesartan significantly reduced plasma levels of malondialdehyde from 1.50 ± 0.07 to 1.29 ± 0.09 µM (p = 0.009); improved the percent flow-mediated dilator response to hyperemia from 5.17 ± 0.24 to 6.22 ± 0.26% (p < 0.001); and, furthermore, reduced plasma levels of monocyte chemoattractant protein (MCP-1) from 213 ± 8 to 190 ± 7 pg/ml (p = 0.003), tumor necrosis factor-alpha from 2.93 to 2.22 pg/ml (p = 0.026), and plasminogen activator inhibitor type 1 from 74 ± 4 to 53 ± 4 ng/ml (p < 0.001) but not C-reactive protein (CRP), matrix metalloproteinase protein, and fibrinogen. There were no significant correlations between these changes and reduction of systolic blood pressure (BP) (–0.247  r 0.195) and between these changes and reduction of diastolic BP (–0.262 r 0.197). There were no significant correlations between markers of inflammation and flow-mediated dilation percent or reduction of oxidant stress (–0.119 r 0.127). Furthermore, we observed no significant correlations between CRP and MCP-1 levels (r = –0.162).
CONCLUSIONS: Inhibition of the angiotensin II type 1 (AT1) receptor in hypertensive patients reverses endothelial dysfunction, measured as an improvement in flow-mediated dilation and fibrinolysis and reduction of oxidant stress and inflammatory cytokines, suggesting that AT1 receptor blocker therapy has antiatherogenic effects.
|
Abbreviations and Acronyms
| | AII | = angiotensin II | | AT1 | = angiotensin II type 1 | | BP | = blood pressure | | CRP | = C-reactive protein | | LDL | = low-density lipoprotein | | MCP | = monocyte chemoattractant protein | | MDA | = malondialdehyde | | MMP | = matrix metalloproteinase protein | NF B | = nuclear transcription factor | | NO | = nitric oxide | | PAI-1 | = plasminogen activator inhibitor type-1 | | TNF | = tumor necrosis factor |
|
This article has been cited by other articles:
|
|
|
|
 
M. White, H. Ross, S. Levesque, L. Whittom, G. B Pelletier, N. Racine, S. Meloche, and L. Voisin
Effects of Angiotensin-Converting Enzyme Inhibitor Versus Valsartan on Cellular Signaling Events in Heart Transplant
Ann. Pharmacother.,
May 1, 2009;
43(5):
831 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kozak, A. Ergul, A. B. El-Remessy, M. H. Johnson, L. S. Machado, H. F. Elewa, M. Abdelsaid, D. C. Wiley, and S. C. Fagan
Candesartan Augments Ischemia-Induced Proangiogenic State and Results in Sustained Improvement After Stroke
Stroke,
May 1, 2009;
40(5):
1870 - 1876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, P. C. Oh, and M. J. Quon
Does reversal of oxidative stress and inflammation provide vascular protection?
Cardiovasc Res,
March 1, 2009;
81(4):
649 - 659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, M. J. Quon, Y. Lee, S. H. Han, J. Y. Ahn, W.-J. Chung, J.-a Kim, and E. K. Shin
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients
Eur. Heart J.,
June 2, 2007;
28(12):
1440 - 1447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, M. J. Quon, S. J. Lee, S. H. Han, J. Y. Ahn, J.-a Kim, W.-J. Chung, Y. Lee, and E. K. Shin
Efonidipine Simultaneously Improves Blood Pressure, Endothelial Function, and Metabolic Parameters in Nondiabetic Patients With Hypertension
Diabetes Care,
June 1, 2007;
30(6):
1605 - 1607.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. de Vinuesa, M. Goicoechea, J. Kanter, M. Puerta, V. Cachofeiro, V. Lahera, F. Gomez-Campdera, and J. Luno
Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade
J. Am. Soc. Nephrol.,
December 1, 2006;
17(12_suppl_3):
S206 - S212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker, E. Danielson, N. Rifai, R. J. Glynn, and for the Val-MARC Investigators
Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC Trial
Hypertension,
July 1, 2006;
48(1):
73 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Festa, K. Williams, R. P. Tracy, L. E. Wagenknecht, and S. M. Haffner
Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes
Circulation,
April 11, 2006;
113(14):
1753 - 1759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Krum, E. Lambert, E. Windebank, D. J. Campbell, and M. Esler
Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension
Am J Physiol Heart Circ Physiol,
April 1, 2006;
290(4):
H1706 - H1712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, M. J. Quon, S. H. Han, W.-J. Chung, J. Y. Ahn, J.-a Kim, Y. Lee, and E. K. Shin
Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients
Diabetes Care,
February 1, 2006;
29(2):
195 - 201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, S. H. Han, and M. J. Quon
Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions
J. Am. Coll. Cardiol.,
December 6, 2005;
46(11):
1978 - 1985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Singh, J. Tabibian, S. K. Venugopal, S. Devaraj, and I. Jialal
Development of an In Vitro Screening Assay to Test the Antiinflammatory Properties of Dietary Supplements and Pharmacologic Agents
Clin. Chem.,
December 1, 2005;
51(12):
2252 - 2256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Watanabe, J. Suzuki, H. Yamawaki, V. K. Sharma, S.-S. Sheu, and B. C. Berk
Losartan Metabolite EXP3179 Activates Akt and Endothelial Nitric Oxide Synthase via Vascular Endothelial Growth Factor Receptor-2 in Endothelial Cells: Angiotensin II Type 1 Receptor-Independent Effects of EXP3179
Circulation,
September 20, 2005;
112(12):
1798 - 1805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, S. H. Han, M. J. Quon, J. Yeal Ahn, and E. K. Shin
Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia
Diabetes Care,
June 1, 2005;
28(6):
1419 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, M. J. Quon, S. H. Han, J. Y. Ahn, D. K. Jin, H. S. Kim, D. S. Kim, and E. K. Shin
Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 Diabetes
Hypertension,
June 1, 2005;
45(6):
1088 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw
Biochemical risk markers: a novel area for better prediction of renal risk?
Nephrol. Dial. Transplant.,
March 1, 2005;
20(3):
497 - 508.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. R. Madamanchi, A. Vendrov, and M. S. Runge
Oxidative Stress and Vascular Disease
Arterioscler Thromb Vasc Biol,
January 1, 2005;
25(1):
29 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, M. J. Quon, S. H. Han, W.-J. Chung, J. Y. Ahn, Y.-H. Seo, M. H. Kang, T. H. Ahn, I. S. Choi, and E. K. Shin
Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients
Circulation,
December 14, 2004;
110(24):
3687 - 3692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Fliser, K. Buchholz, H. Haller, and for the EUropean Trial on Olmesartan and Pravastat
Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation
Circulation,
August 31, 2004;
110(9):
1103 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yasunari, K. Maeda, T. Watanabe, M. Nakamura, J. Yoshikawa, and A. Asada
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy
J. Am. Coll. Cardiol.,
June 2, 2004;
43(11):
2116 - 2123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
